Abstracts and Clinical Summary: Decreased Readmissions, LOS and Episode Cost
Oral Nutrition Supplements’ Impact on Hospital Outcomes in the Context of The Affordable Care Act and New Medicare Reimbursement Policies
In 2014, a retrospective health economic outcome study by Lakdawalla showed that ONS use was associated with reductions in probability of 30-day readmission by 12.0% in acute myocardial infarction (AMI) and 10.1% in congestive heart failure (CHF). Length of stay (LOS) decreases of 10.9% in AMI, 14.2% in CHF, and 8.5% in pneumonia (PNA) were associated with ONS, as were decreases in episode costs in AMI, CHF and PNA of 5.1%, 7.8% and 10.6%, respectively. The effect on LOS and episode cost was greatest for the Any Diagnosis population, with decreases of 16.0% and 15.8%, respectively.
The Impact of Oral Nutritional Supplementation in Medicare Patients with COPD
In 2014, a retrospective health economic outcome study published in CHEST by Snider showed out of 10,322 ONS hospitalizations and 368,097 non-ONS hospitalizations, ONS use was associated with: a 1.88 day (21.5%) decrease in LOS, from 8.75 to 6.87 days (p<0.01); hospitalization cost 17 reduction of $1,570 (12.5%), from $12,523 to $10,953 (p<0.01); and a 13.1% decrease in probability of 30-day readmission, from 0.335 to 0.291 (p<0.01).
Impact of Oral Nutritional Supplementation (ONS) on Hospital Outcomes
This health economic study demonstrated that oral nutritional supplements provided during hospitalization were associated with decreased length of stay and episode costs. In patients with at least one known follow-up, there was a 6.7% decrease in probability of 30-day hospital readmissions.*